Literature DB >> 21349584

Integrin α(5) interacts with EGFR, is necessary for FcɛRI signaling and is necessary for allergic inflammation in relation with angiogenesis.

Youngmi Kim1, Kyungjong Kim, Deokbum Park, Sangkyung Eom, Hyunmi Park, Hansoo Lee, Yun-Sil Lee, Jongseon Choe, Jang-Hee Hahn, Young-Myeong Kim, Jai Youl Ro, Dooil Jeoung.   

Abstract

Recent reports have suggested role for epidermal growth factor receptor (EGFR) in asthma and skin inflammation. Integrin(s) are known to be necessary for the transactivation of EGFR. The roles of EGFR and integrin(s) in allergic inflammation were investigated. Antigen stimulation induced activation of EGFR and interaction between EGFR and integrin α(5) in Rat Basophilic Leukemia (RBL2H3) cells and bone marrow-derived mouse mast cells (BMMCs). Flow cytometry revealed increased phosphorylation of EGFR on cell surfaces. Antigen stimulation induced interaction between EGFR and FcɛRI in both RBL2H3 cells and BMMCs. Blocking of EGFR or integrin α exerted negative effects on rac1 activity and secretion of β-hexosaminidase in both RBL2H3 cells and BMMCs. EGFR and integrin α(5) were found to be necessary for IgE-dependent cutaneous anaphylaxis. FAK (focal adhesion kinase), interacted with EGFR and with FcɛRI upon antigen stimulation, and it was necessary for the increased secretion of β-hexosaminidase in both RBL2H3 cells and BMMCs. EGFR and integrin α(5) were necessary for interactions between activated RBL2H3 cells, BMMCs and rat aortic endothelial cells (RAECs). Conditioned medium of antigen-stimulated RBL2H3 cells promoted RAECs tube formation, rat aortic ring formation and blood vessel formation. Conditioned medium of antigen-stimulated BMMCs also had the same effects on RAECs. This enhanced angiogenic potential of RAECs was dependent on EGFR and integrin α(5). In conclusion, EGFR, via interaction with FcɛRI and integrin α(5), is necessary for allergic inflammation associated with cellular interaction.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21349584     DOI: 10.1016/j.molimm.2011.01.013

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  6 in total

1.  MicroRNA-26a/-26b-COX-2-MIP-2 Loop Regulates Allergic Inflammation and Allergic Inflammation-promoted Enhanced Tumorigenic and Metastatic Potential of Cancer Cells.

Authors:  Yoojung Kwon; Youngmi Kim; Sangkyung Eom; Misun Kim; Deokbum Park; Hyuna Kim; Kyeonga Noh; Hansoo Lee; Yun Sil Lee; Jongseon Choe; Young Myeong Kim; Dooil Jeoung
Journal:  J Biol Chem       Date:  2015-04-23       Impact factor: 5.157

2.  Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.

Authors:  Youngmi Kim; Kyungjong Kim; Deokbum Park; Eunmi Lee; Hansoo Lee; Yun-Sil Lee; Jongseon Choe; Dooil Jeoung
Journal:  J Biol Chem       Date:  2012-06-07       Impact factor: 5.157

3.  Transglutaminase II/microRNA-218/-181a loop regulates positive feedback relationship between allergic inflammation and tumor metastasis.

Authors:  Sangkyung Eom; Youngmi Kim; Misun Kim; Deokbum Park; Hansoo Lee; Yun Sil Lee; Jongseon Choe; Young Myeong Kim; Dooil Jeoung
Journal:  J Biol Chem       Date:  2014-09-08       Impact factor: 5.157

4.  Genome-wide scan on total serum IgE levels identifies no common variants in a healthy Chinese male population.

Authors:  Ming Liao; Dianchun Shi; Yao Wang; Kai Zhang; Xin Chen; Yong Gao; Aihua Tan; Qiang Xuan; Xiaobo Yang; Yanlin Hu; Xue Qin; Haiying Zhang; Zengnan Mo
Journal:  Immunogenetics       Date:  2013-05-10       Impact factor: 2.846

5.  Lymphatic vascular response to acute inflammation.

Authors:  Pier-Anne Lachance; Amy Hazen; Eva M Sevick-Muraca
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

Review 6.  FcεRI-HDAC3-MCP1 Signaling Axis Promotes Passive Anaphylaxis Mediated by Cellular Interactions.

Authors:  Misun Kim; Yoojung Kwon; Hyun Suk Jung; Youngmi Kim; Dooil Jeoung
Journal:  Int J Mol Sci       Date:  2019-10-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.